Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: The Swiss HIV Cohort Study

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 2, 2012, Pages 135-142

  Bucher, Heiner C ^a,b   Richter, Werner ^c   Glass, Tracy R ^a   Magenta, Lorenzo ^d   Wang, Qing ^a   Cavassini, Matthias ^e   Vernazza, Pietro ^f   Hirschel, Bernard ^g   Weber, Rainer ^h   Furrer, Hansjakob ⁱ   Battegay, Manuel ^a   Bernasconi, Enos ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Institute for Lipid Metabolism   (Germany)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antiretroviral therapy; Apolipoprotein B; Coronary heart disease; HIV infection; LDL cholesterol; Small dense LDL

Indexed keywords

ABACAVIR; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SUDDEN DEATH; TRANSLUMINAL CORONARY ANGIOPLASTY; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY DISEASE; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK ASSESSMENT; SWITZERLAND; YOUNG ADULT;

EID: 84862151357     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824476e1     Document Type: Article

References (47)

1. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193. (Pubitemid 36667761)
2. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982. (Pubitemid 37430100)
3. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
4. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study. J Infect Dis. 2010;201:318-330.
5. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211-217. (Pubitemid 46602300)
6. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-559. (Pubitemid 40315677)
7. Arsenault BJ, Lemieux I, Despres JP, et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPICNorfolk prospective population study. Eur Heart J. 2007;28:2770-2777. (Pubitemid 350135531)
8. Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal.J Clin Endocrinol Metab. 2003;88:4525-4532. (Pubitemid 37357487)
9. Badiou S, Merle De BC, Dupuy AM, et al. Decrease in LDL size in HIVpositive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis. 2003;168:107-113. (Pubitemid 36555817)
10. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2008;48:281-288.
11. Schmitz M, Michl GM, Walli R, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy.J Acquir Immune Defic Syndr. 2001;26:225-235. (Pubitemid 32246552)
12. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV cohort study. Int J Epidemiol. 2009;39:1179-1189.
13. Friis-Moller N, Sabin CA,Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
14. Lubin JH. Extensions of analytic methods for nested and populationbased incident case-control studies. J Chronic Dis. 1986;39:379-388. (Pubitemid 16099617)
15. Robins JM, Gail MH, Lubin JH. More on "biased selection of controls for case-control analyses of cohort studies". Biometrics. 1986;42:293-299.
16. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case-control studies. III. Design options. Am J Epidemiol. 1992;135: 1042-1050.
17. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059-1062. (Pubitemid 41338752)
18. Essebag V, Genest J Jr, Suissa S, et al. The nested case-control study in cardiology. Am Heart J. 2003;146:581-590. (Pubitemid 37281701)
19. Lachin JM. Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. Stat Med. 2008;27:2509-2523. (Pubitemid 351982689)
20. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17:3542-3556. (Pubitemid 28028567)
21. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-1379.
22. Campos H, Walsh BW, Judge H, et al. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab. 1997;82:3955-3963. (Pubitemid 27525494)
23. Packard CJ, Demant T, Stewart JP, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res. 2000; 41:305-318.
24. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19(suppl A):A24-A30. (Pubitemid 28112474)
25. Kim DS, Kim YK, Kim DS, et al. Low-density lipoprotein particle size in hepatic steatosis andmetabolic syndrome. DiabetolMetab Syndr. 2010;2:18.
26. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512-1524. (Pubitemid 351470037)
27. Albers JJ, Kennedy H, Marcovina SM. Evaluation of a new homogenous method for detection of small dense LDL cholesterol: Comparison with the LDL cholesterol profile obtained by density gradient ultracentrifugation.Clin Chim Acta. 2010;412:1181-1187.
28. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med.2007;357:1009-1017.
29. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. (Pubitemid 39208455)
30. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033. (Pubitemid 34084825)
31. Magenta L, Dell-Kuster S, Richter WO, et al. Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2010;27:525-533.
32. Umpleby AM, Das S, Stolinski M, et al. Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy. Antivir Ther. 2005;10:663-670. (Pubitemid 41224958)
33. Catzin-Kuhlmann A, Castillo-Martinez L, Colin-Ramirez E, et al. No evidence of increased risk for certain highly atherogenic lipoprotein phenotypes in HIV-infected patients. Arch Med Res. 2008;39:84-91. (Pubitemid 350192002)
34. Badiou S, Thiebaut R, Aurillac-Lavignolle V, et al. Association of non- HDL cholesterol with subclinical atherosclerosis in HIV-positive patients.J Infect. 2008;57:47-54.
35. Briel M, Studer M, Glass TR, et al. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004;117:596-606. (Pubitemid 39304211)
36. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.BMJ. 2009;338:B92.
37. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med.2005;165:725-730. (Pubitemid 40569423)
38. Brunzell JD. Increased ApoB in small dense LDL particles predicts premature coronary artery disease. Arterioscler Thromb Vasc Biol. 2005;25:474-475. (Pubitemid 40315664)
39. Badiou S, Merle De BC, Dupuy AM, et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004;172:273-279. (Pubitemid 38167538)
40. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6:15.
41. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
42. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843. (Pubitemid 30165206)
43. van Vonderen MG, Hassink EA, van Agtmael MA, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis. 2009;199:1186-1194.
44. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis. 2010;23:9-14.
45. Costagliola D, Lang S, Mary-Krause M, et al. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep. 2010;7:127-133.
46. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993-2004.
47. Saumoy M, Ordonez-Llanos J, Martinez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther. 2011;16:459-468.